CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Review CIRB
Study Status
Study Number Sort descending Lead Group Study Title CIRB Study Status
ADVL1414 COG A Phase 1 Study of Selinexor (KPT-330; IND #125052); A Selective XPO1 Inhibitor; In Recurrent and Refractory Pediatric Solid Tumors; Including CNS Tumors Pediatric CIRB Available to Open
ADVL1416 COG A Phase 1 study of Ramucirumab; a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors; including CNS Tumors Pediatric CIRB Available to Open
ADVL1513 COG A Phase 1 Study of Entinostat; An Oral Histone Deacetylase Inhibitor; In Pediatric Patients with Recurrent or Refractory Solid Tumors; Including CNS Tumors and Lymphoma Pediatric CIRB Completed
ADVL1514 COG A Phase 1 Study of ABI-009 (nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan Pediatric CIRB Available to Open
ADVL1515 COG A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors Pediatric CIRB Completed
ADVL1521 COG A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia Pediatric CIRB Available to Open
ADVL1522 COG A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953; NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor; Rhabdomyosarcoma; Neuroblastoma; Pleuropulmonary Blastoma; Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma Pediatric CIRB Completed
ADVL1614 COG A Phase 1/2 Study of VX15/2503 (IND #136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors Pediatric CIRB Available to Open
ADVL1615 COG A Phase 1 Study of Pevonedistat (MLN4924, IND # 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors Pediatric CIRB Available to Open
ADVL1622 COG Phase 2 Trial of XL184 (Cabozantinib); an Oral Small-Molecule Inhibitor of Multiple Kinases; in Children and Young Adults with Refractory Sarcomas; Wilms Tumor; and Other Rare Tumors Pediatric CIRB Available to Open